ARCHIVES

FDA Says Bristol’s UFT “Not Approvable” For Colorectal Cancer, Contrary To ODAC.

This article is from The Cancer Letter archive.

Vol. 27 No. 13 | March 30, 2001

Download PDF Visit The Full Archive

Related Articles

ODAC Oks Melphalan Injection WR-2721 Needs More Data

February 7, 1992

Long-term Follow-up Shows ADH and ALH Tissue Abnormalities Can Carry Similar Risk

January 31, 2014

HCFA Chief Says Facts Will Not Matter, She Won’t Loosen DRGs For Clinical Trials Unless Congress Orders It

May 4, 1984

Letter: Medicare Policy May Delay Access to Cancer Drugs

June 13, 2003

NCI Picks 11 Centers For Chemical Biology Consortium

October 23, 2009

In Congress: Societies, Advocates, Testify For Increases In Research Funding

February 13, 1998